| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-07-31 |
Uniqure (The Netherlands) Chiesi Farmaceutici (Italy) |
Glybera®, gene therapy for hemophilia B (alipogene tiparvovec) |
lipoprotein lipase deficiency demonstrating hyperchylomicronaemia or having a history of acute pancreatitis, hemophilia B |
co-developement, commercialisation |
Rare diseases - Genetic diseases |
Termination of an agreement |
| 2017-07-31 |
Onxeo (France) Vectans Pharma (France) |
Sitavig® (acyclovir Lauriad™), Loramyc® (miconazole Lauriad™) |
labial herpes, oropharyngeal candidiasis |
product acquisition |
Infectious diseases |
Product acquisition |
| 2017-07-31 |
Loxo Oncology (USA - CT) Redx Pharma (UK) |
Bruton's tyrosine kinase (BTK) inhibitor program including LOXO-305 (formerly RXC005) |
|
product acquisition |
Cancer - Oncology |
Product acquisition |
| 2017-07-31 |
BMS (USA - NY) Clovis Oncology (USA - CO) |
- enzyme inhibitor/PARP inhibitor/monoclonal antibody/immune chekcpoint inhibitor.
- Rucaparib is an orally-available, small molecule PARP 1 (poly ADP-ribose polymerase) and PARP2 inhibitor being developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as “BRCA-like” or “BRCAness.”
- BRCA genes are involved with repairing damaged DNA and normally work to prevent tumor development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. By blocking PARP enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slow-down or stoppage of tumor growth.
- Nivolumab is a fully-human PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T-cells. By blocking this pathway, nivolumab enables the immune system to resume its ability to recognize, attack and destroy cancer cells.
|
advanced ovarian cancer, advanced fallopian tube cancer, primary peritoneal canceradvanced triple-negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC) |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-07-30 |
HiFiBiO Therapeutics (USA - MA) Takeda Pharmaceutical (Japan) |
antibody therapies for the treatment of various gastrointestinal diseases, cancers and other disorders |
|
research - licensing |
Cancer - Oncology - Gastrointestinal diseases - Digestive diseases |
Licensing agreement |
| 2017-07-27 |
Galapagos (Belgium) Servier (France) |
small molecule candidate drugs including GLPG1972/S201086 |
osteoarthritis |
R&D - development - licensing |
Rheumatic diseases - Inflammatory diseases – Bone diseases |
Exercise of an option agreement |
| 2017-07-27 |
Alexion Pharmaceuticals (USA - CT) Blueprint Medicines (USA - MA) |
novel drug candidates for an undisclosed activated kinase target |
undisclosed rare genetic disease |
R&D - development - commercialisation |
Rare diseases - Genetic diseases |
Termination of an agreement |
| 2017-07-27 |
Complix (Belgium) Merck&Co (USA - NJ) |
Cell-Penetrating Alphabodies (CPABs) |
|
R&D - research |
Cancer - Oncology |
Exercise of an option agreement |
| 2017-07-27 |
Moderna Therapeutics (USA - MA) Alexion Pharmaceuticals (USA - CT) |
messenger RNA Therapeutics™ |
|
development |
Rare diseases |
Termination of an agreement |
| 2017-07-27 |
Arbutus Biopharma (Canada) Alexion Pharmaceuticals (USA - CT) |
lipid nanoparticle (LNP) technology |
chronic hepatitis B |
licensing |
Infectious diseases |
Termination of an agreement |
| 2017-07-27 |
Takeda Pharmaceutical (Japan) Tesaro (US - MA) |
niraparib |
|
licensing - devlopment - commercialisation |
Cancer - Oncology |
Licensing agreement |
| 2017-07-27 |
AstraZeneca (UK) Merck&Co (USA - NJ) |
Imfinzi® (durvalumab), Keytruda® (pembrolizumab), Lynparza® (olaparib), selumetinib |
|
collaboration - development |
Cancer - Oncology |
Collaboration agreement |
| 2017-07-27 |
Infinity Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan) Millennium Pharmaceuticals (USA - MA) |
IPI-549 |
|
licensing |
Cancer - Oncology |
Licensing agreement |
| 2017-07-27 |
Biomarin Pharmaceutical (USA - CA) |
expansion in BioMarin Shanbally |
|
opening of new premises |
Rare diseases - Genetic diseases |
Opening of new premises |
| 2017-07-26 |
Emergent BioSolutions (USA - MD) Valneva (France - Austria) |
ZIKV-VLA1601 |
Zika virus infection |
licensing - collaboration |
Infectious diseases |
Licensing agreement |
| 2017-07-26 |
Jazz Pharmaceuticals (Ireland) XL-Protein (Germany) |
- PASylation® Technology applied to selected asparaginase product candidates
|
|
licensing |
|
Licensing agreement |
| 2017-07-25 |
BioSurfaces (USA - MA) Takeda Pharmaceutical (Japan) |
medical devices using BioSurfaces’ proprietary nanomaterial technology. |
gastrointestinal diseases |
research |
Gastrointestinal diseases |
Research agreement |
| 2017-07-25 |
Abeona Therapeutics (USA - NY) |
chief medical officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-07-25 |
Molmed (Italy) Dompé (Italy) |
Zalmoxis® |
leukaemia or other high-risk haematological malignancies, in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT) |
commercialisation - supply |
Cancer - Oncology - Rare diseases |
Commercialisation agreement |
| 2017-07-24 |
Eli Lilly (USA - IN) Nektar Therapeutics (USA - CA) |
NKTR-358 |
|
development - commercialisation |
Autoimmune diseases – Inflammatory diseases |
Development agreement |
